SCHEMBL6510874

SCHEMBL6510874

O=c1[nH]c2ccc(Cl)cc2c2nn(C3CCCCO3)c(CCOCc3ccccc3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.38
PYGL P06737 1/20 0.37
IDH1 O75874 1/20 0.37
ALDH1A1 P00352 5/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HSD17B10 Q99714 3/20 0.35
KDM4E B2RXH2 3/20 0.35
ALOX15 P16050 2/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
GAA P10253 2/20 0.35
CHEK1 O14757 1/20 0.35
NPSR1 Q6W5P4 3/20 0.35
CASP1 P29466 1/20 0.35
MAPK10 P53779 1/20 0.34
ATR Q13535 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6510232 0.97 ADORA3 (0.37) ADORA3PYGLIDH1ALDH1A1MAPT
SCHEMBL6515300 0.88 CHEK1 (0.39) ADORA3IDH1ALDH1A1MAPTMEN1
SCHEMBL6508340 0.88 IDH1 (0.39) ADORA3IDH1ALDH1A1MAPTMEN1
SCHEMBL6508818 0.88 CHEK1 (0.39) ADORA3PYGLIDH1ALDH1A1MAPT
SCHEMBL6522020 0.83 CHEK1 (0.43) ADORA3IDH1ALDH1A1MAPTMEN1
SCHEMBL6510097 0.79 IDH1 (0.41) ADORA3IDH1ALDH1A1MAPTMEN1
SCHEMBL6508753 0.78 CHEK1 (0.47) ADORA3IDH1ALDH1A1MAPTMEN1
SCHEMBL6522360 0.74 ATR (0.39) ADORA3ALDH1A1MAPTKMT2AKDM4E
SCHEMBL6509557 0.73 CHEK1 (0.53) ADORA3ALDH1A1MAPTMEN1KMT2A
SCHEMBL6510810 0.72 ATR (0.38) ADORA3ALDH1A1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 ADORA3 4827/4885PYGL 693/4885IDH1 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.